Aldosterone Synthase Inhibition in Kidney Transplantation: Class Rationale, Translational Promise, and the Limits of...

Area of Science:

• Nephrology
• Pharmacology
• Cardiovascular Medicine

Background:

• Post-kidney transplant hypertension is common, often linked to calcineurin inhibitors (CNIs) causing sodium retention and vasoconstriction.
• Sodium-chloride cotransporter (NCC) inhibition is a primary therapy for this salt-sensitive hypertension.
• Aldosterone synthase inhibitors (ASIs) represent an emerging drug class with potential therapeutic relevance.

Purpose of the Study:

• To examine aldosterone synthase inhibitors (ASIs) as a potential adjunctive therapy for resistant hypertension in kidney transplant recipients.
• To review the rationale, development, and current status of ASIs, including baxdrostat, lorundrostat, and vicadrostat.
• To identify the unique challenges and considerations for ASI use in kidney transplant recipients.

Main Methods:

• Review of existing data on ASIs in non-transplant populations with uncontrolled or resistant hypertension.
• Analysis of ASI efficacy and safety profiles, including cardiorenal promise and combination development.
• Identification of research gaps, particularly the lack of ASI studies in kidney transplant recipients.

Main Results:

• ASIs like baxdrostat and lorundrostat have demonstrated blood pressure reduction in non-transplant hypertensive populations.
• Vicadrostat has shown potential in chronic kidney disease, with ongoing combination studies.
• No ASI has been evaluated in kidney transplant recipients to date.

Conclusions:

• ASIs are investigational agents for kidney transplant recipients, not current recommendations.
• Transplant recipients present unique challenges: reduced nephron reserve, CNI exposure, and narrow potassium margins.
• Future trials must prioritize hyperkalemia monitoring, NCC-directed therapy comparators, and immunosuppressant interaction assessments.